We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -0.75 (-1.78%)
Spread: 1.00 (2.439%)
Open: 42.25
High: 42.00
Low: 41.50
Prev. Close: 42.25
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Lloyds Pharmacy to list UltraDEX in UK

4 Jun 2018 07:00

RNS Number : 1086Q
Venture Life Group PLC
04 June 2018
 

Venture Life Group plc

("Venture Life" or the "Company")

 

Lloyds Pharmacy to list UltraDEX in UK

New international partnering deal signed

 

Venture Life (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, announces an update on the UltraDEX brand and a new international distribution agreement for the Myco Clear brand.

 

The Company announces the launch of UltraDEX in Lloyds Pharmacy in the UK from 18 June 2018. Initially, this will bring the brand an additional 580 new listings through the introduction in stores of UltraDEX Oral Rinse and UltraDEX Fresh Breath spray. In addition, Lloyds Pharmacy will list these two products, plus the UltraDEX Toothpaste in their online store, where it will be available to purchase online or via click and collect in store.

 

Lloyds Pharmacy is a leading community pharmacy and healthcare provider with over 1,500 pharmacies across the UK, mainly in community and health centre locations.

 

In addition, and as previously announced, Superdrug is launching the new UltraDEX One GOÔ range in 797 stores in the UK from 4 June 2018. UltraDEX One GOÔ is a new and innovative line extension from the Company, providing single use sachets of the clinically proven UltraDEX mouthwash.

 

Separately, the Company also announces a new distribution deal with the international pharmaceutical company Jaba Recordati S.A. ("Jaba") in Portugal for Myco Clear™, a range that helps treat and prevent nail fungal infections. Launch will take place later this year, or Q1 2019.

 

Commenting Chief Executive Officer, Jerry Randall, said: "I am delighted that we have now been able to get the UltraDEX range into Lloyds Pharmacy, the second largest chain of pharmacies in the UK. Our store listings are now 20% higher than one year ago - this reflects the continued commercial development of the UltraDEX brand in the UK. This increase of distribution also illustrates the growing momentum of the brand along with the launch of the new UltraDEX One GOÔ in Superdrug. We have seen a high level of interest in the new products developed for the UltraDEX range and expect to provide further news in this area soon."

 

I am also delighted to announce the new distribution agreement of Myco Clear with Jaba, who are a significant player in the European OTC market. This opportunity adds to a number of products we already supply to the Recordati Group. The adoption of Myco Clear by such a prestigious company validates the innovative and high quality nature of our products in this area."

 

 

 For further information please contact:

 

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton (Corporate Finance)

John Howes / Vadim Alexandre (Corporate Broking) 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope / Ben Turner

Walbrook PR

venturelife@walbrookpr.com or + 44 (0) 20 7933 8780

Anna Dunphy /Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMGGVRMDGRZM
Date   Source Headline
19th Apr 20247:00 amRNSRCF in Place and New Partner in the USA
9th Apr 20247:00 amRNSFinal Results for year ended 31 December 2023
4th Apr 20247:00 amRNSNotice of Results and Investor Presentation
19th Feb 20245:18 pmRNSHolding(s) in Company
6th Feb 202410:48 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTrading Update
20th Dec 20232:00 pmRNSHolding(s) in Company
28th Nov 202312:28 pmRNSHolding(s) in Company
22nd Nov 20234:05 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSChange of Nominated Adviser and Broker
31st Oct 20233:11 pmRNSHolding(s) in Company
17th Oct 20231:54 pmRNSHolding(s) in Company
25th Sep 20237:01 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSTrading Statement
5th Jul 20237:00 amRNSPDMR Shareholdings – Grant of Awards
26th Jun 20234:48 pmRNSDirector/PDMR Shareholding
25th May 20231:54 pmRNSDirector Dealings
22nd May 20233:01 pmRNSResults of AGM
22nd May 20237:00 amRNSAGM Statement
19th May 20237:00 amRNSBoard Change
9th May 20237:00 amRNSNotice of Capital Markets Event
28th Apr 202310:05 amRNSAnnual Report and Notice of AGM
5th Apr 20231:53 pmRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSFinal Results for year ended 31 December 2022
31st Mar 20237:00 amRNSInvestor Presentation
13th Mar 20237:00 amRNSUpdate re Revolving Credit Facility
10th Mar 20232:05 pmRNSSecond Price Monitoring Extn
10th Mar 20232:00 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSTrading Statement
9th Jan 20237:00 amRNSLicensing and distribution agreements
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn
1st Dec 20224:37 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAcquisition and trading update
10th Oct 20227:00 amRNSDirectorate Changes
23rd Sep 202211:08 amRNSInvestor Presentation
22nd Sep 20227:00 amRNSHalf-year Report
25th Jul 202212:00 pmRNSDirector/PDMR Shareholding
25th Jul 20227:00 amRNSTrading Update
20th Jun 20222:31 pmRNSResults of AGM
10th Jun 202212:21 pmRNSDirector/PDMR Shareholding
9th Jun 20225:53 pmRNSAnnual Report & Notice of AGM - Correction
7th Jun 20227:00 amRNSAnnual Report & Notice of AGM
30th May 20224:22 pmRNSDirector/PDMR Shareholding
30th May 20227:00 amRNSDirectorate Changes
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 20227:00 amRNSInvestor Presentation
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.